@article {2268, title = {Evaluation of Serum Eta Protein, Sclerostin, and Calcitonin Level in Arthritis Patients on Vitamin D Therapy}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {April 2024}, pages = {426-430}, type = {Research Article}, chapter = {426}, abstract = {

Background: Arthritis is an inflammatory condition affecting the diarthrodial joints. A joint{\textquoteright}s bone, cartilage, and structural design all preserve its integrity, and arthritis alters that integrity, resulting in joint activity loss and discomfort. The primary symptom of arthritis is joint pain, although other symptoms include stiffness, inflammation, and impaired joint motor function. Methods: The cross-sectional study comprised 90 subjects: 70 arthritis sufferers and 20 controls, ages 25-60, both sexes. From September 2023 to March 2024, patients were referred to Kirkuk city in Azadi hospital and Kirkuk general hospital. The research participants were placed into three groups: Group 1 for arthritic patients without Vit D (35). Patients with arthritis who received vitamin D for at least two months (G2), n (35), were the second group. The third group comprised healthy individuals without arthritis n (20). Result: Significant (P\<0.05) increase in ETA protein levels in G1 and G2 compared to G3. G1 had ETA protein levels of 28.05{\textpm}5.34 ng/L, G2 had 24.10{\textpm}3.67 ng/L, and G3 had 8.92{\textpm}2.80 ng/L. Sclerostin levels peaked in G1 (0.4273{\textpm}0.3023 pg/mL) and declined in G2 (P\<0.05) compared to G3. Calcitonin levels were higher in G1 (34.72{\textpm}4.72 pg/mL) and G2 (27.06{\textpm}5.85 pg/mL) than G3 (14.71{\textpm}3.71 pg/mL) at (P\<0.05). Conclusion: The study found a rise in ETA protein and calcitonin levels in arthritic patients before and after therapy with vitamin D, which was not influenced by vitamin supplementation. Sclerostin levels increase in arthritic patients and decrease following therapy with vitamin D.

}, keywords = {Arthritis, Calcitonin, ETA protein, Sclerostin, Vitamin D}, doi = {10.5530/pj.2024.16.67}, author = {Soma A. Mohammed and Entedhar R. Sarhat} } @article {2269, title = {The Role of Vitamin D-Binding Protein, and Procalcitonin in Patients with Arthritis on Vitamin D}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {April 2024}, pages = {431-435}, type = {Research Article}, chapter = {431}, abstract = {

Background: Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, swelling, and decreased range of motion of the affected joints. In some types of arthritis, other organs are also affected. Aim: This study aimed to identify the impact of vitamin D therapy on serum level of vitamin D-binding protein and procalcitonin in Patients with arthritis. Methods: This cross-sectional study, was conducted in Kirkuk city between January 1st and March 1st, 2024. A total of 180 subjects were included, categorized into three groups: arthritis patients not receiving vitamin D (Group 1), arthritis patients receiving vitamin D for at least 2 months (Group 2), and a control group comprising 40 healthy subjects. Blood samples were collected from participants, processed, and stored for subsequent analysis. Various biomarkers, including vitamin D-binding protein and procalcitonin, were determined using ELISA kits. Results: The study revealed a higher prevalence of females among arthritis patients (54.29\%), with most affected individuals aged above 60 years. Urban residency was predominant among arthritis patients (75.71\%). The majority of RA patients had been affected for 6-10 years (40\%). Comparative analysis demonstrated significantly higher procalcitonin levels in RA patients without vitamin D supplementation (112.4{\textpm}24.3 ng/ ml) compared to those with supplementation (48.33{\textpm}10.73 ng/ml) and healthy controls (9.68{\textpm}5.49 ng/ ml). Furthermore, vitamin D binding protein levels were significantly lower in arthritis patients without supplementation (1.26{\textpm}0.12 ng/ml) compared to those with supplementation (0.75{\textpm}0.15 ng/ml) and healthy controls (0.23{\textpm}0.14 ng/ml). Conclusion: These findings underscore the potential role of vitamin D supplementation in modulating inflammatory markers and enhancing vitamin D binding protein levels in arthritis patients, suggesting its therapeutic implications in disease management.

}, keywords = {Arthritis, Procalcitonin, Vitamin D, Vitamin D-binding Protein}, doi = {10.5530/pj.2024.16.68}, author = {Mardin M. Obied and Entedhar R. Sarhat} }